Terry

Bristol-Myers Squibb Puts Its Hat Into The Ring In Targeting 1st-Line Liver Cancer With OPDIVO-Based Regimen

Opthea Runs Out Of Options With Failed Wet-AMD Studies, Reduces Workforce By 65%

To Get Phase 3 Program Going Tempest Seeks Strategic Alternatives For Amezalpat For Liver Cancer

Bristol-Myers Squibb Nabs FDA Regulatory Wins With OPDIVO And Yervoy Combination For CRC

Rallybio Scraps Maternal Disorder Candidate RLYB212 Shifting Focus To C5 Inhibitor

Rhythm Pharmaceuticals Scores A Win For Obesity Disorder Caused By Impairment Of The Brain

Beigene’s Anti-TIGIT Trial Closure Doesn’t Bode Well For This Drug Class Going Forward

Sangamo Gets Lifeline From Eli Lilly In $1.4 Billion Dollar Deal For Proprietary AAV Capsid

Second FDA Rejection Of Aldeyra Therapeutics But Hope Remains With Two Upcoming Events

Latest Corcept Data Could Lead To New Standard Of Care Option for Platinum-Resistant Ovarian Cancer Patients

Cassava Sciences Scraps Alzheimer’s Drug Development Of Simufilam After Latest Trial Failure

Lexicon Establishes $1 Billion Milestone Deal With Novo Nordisk To Advance Weight Loss Drug LX9851

Scroll to Top